Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer
Open Access
- 15 July 2017
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cancer Immunology, Immunotherapy
- Vol. 66 (10), 1249-1264
- https://doi.org/10.1007/s00262-017-2025-8
Abstract
Oncolytic immunotherapy is a research area of cancer immunotherapy investigating the use of modified viruses to target cancer cells. A variety of different viral backbones (e.g., adenovirus, reovirus) with a diverse range of genetic modifications are currently being investigated for the treatment of a variety of cancers. The oncolytic virus that has advanced the furthest in clinical development is talimogene laherparepvec, a recombinant HSV-1 virus expressing granulocyte-macrophage colony-stimulating factor (GM-CSF). In a phase 3 study in patients with unresectable metastatic melanoma, intralesional talimogene laherparepvec treatment resulted in a higher durable response rate compared with subcutaneous GM-CSF treatment (16.3 versus 2.1%; P < 0.001). Notably, responses were observed at uninjected lesions including visceral lesions, indicating a systemic antitumor response had occurred. Studies evaluating combination treatments involving oncolytic viruses and immunologic agents are ongoing. This review focuses on the mechanisms of action for oncolytic viruses and highlights select agents and combinations currently in development.Keywords
Funding Information
- Amgen
This publication has 82 references indexed in Scilit:
- Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancerNature Medicine, 2013
- A First in Human Phase 1 Study of CG0070, a GM-CSF Expressing Oncolytic Adenovirus, for the Treatment of Nonmuscle Invasive Bladder CancerJournal of Urology, 2012
- Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapyBlood, 2012
- Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4Gene Therapy, 2011
- Thunder and Lightning: Immunotherapy and Oncolytic Viruses CollideMolecular Therapy, 2011
- Chemokine Expression From Oncolytic Vaccinia Virus Enhances Vaccine Therapies of CancerMolecular Therapy, 2011
- Oncolytic Viruses for Cancer Therapy: Overcoming the ObstaclesViruses, 2010
- Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic MelanomaJournal of Clinical Oncology, 2009
- Oncolytic viruses: a novel form of immunotherapyExpert Review of Anticancer Therapy, 2008
- THE INFLUENCE OF COMPLICATING DISEASES UPON LEUKÆMIA.*The American Journal of the Medical Sciences, 1904